- Text-only version of this website
- Skip navigation
- Home page
- What's new
- Contact Webmaster
- Website policies
- Disability services
|A Trial Comparing Cardiovascular Safety of Insulin Degludec Versus Insulin Glargine in Subjects With Type 2 Diabetes at High Risk of Cardiovascular Event (DEVOTE)||Margaret Lo, M.D.
|Effect of Aerobic Interval Training on Cardiovascular Function in Type 2 Diabetes||Demetra Christou, Ph.D.
|Sattari, Maryam, M.D.
|SONAR: Study Of Diabetic Nephropathy with Atrasentan||Karen Hall, M.D.
|A Randomized, Double-Blind, Placebo-controlled, Parallel-group Study to Evaluate the Effect of Long-term Treatment with BELVIQ (lorcaserin HCI) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects with Cardiovascular Disease or Multiple Cardiovascular Risk Factors CAMELLIA||Dominick J. Angiolillo, M.D., Ph.D.
|A Trial Comparing Cardiovascular Safety of Insulin Degludec Versus Insulin Glargine in Subjects with Type 2 Diabetes at High Risk of Cardiovascular Events||Joe Chehade, M.D.
|A Clinical Evaluation of Absorb™ BVS, the Everolimus Eluting Bioresorbable Vascular Scaffold in the Treatment of Subjects with de novo Native Coronary Artery Lesion (ABSORB III)||